# Molnupiravir

## Molnupiravir 200mg (公費) Lagevrio

| TAH Drug Code      | [OMOL](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMOL)                                                                                                                                                                                                                                                                |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | An Emergency Use Authorization (EUA) for the emergency use of Molnupiravir for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in certain adults who are at high-risk for progression to severe COVID-19.                                                                                                     |
| Dosing             | 800 mg (four 200-mg capsules) orally every 12 hours for 5 days with or without food; administer as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                       |
| Contraindications  | NOT for use in patients who are less than 18 years of age. NOT for initiation of treatment in patients requiring hospitalization due to COVID-19. NOT for use for longer than 5 consecutive days. NOT for use as pre-exposure or as post-exposure prophylaxis for prevention of COVID-19. Not recommended for use during pregnancy. |
| Adverse Effects    | Common Gastrointestinal: Diarrhea (2% to 3% )， Nausea (2% ) Neurologic: Dizziness (1% )， Headache (1% )                                                                                                                                                                                                                           |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                             |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information)                                                                                                                                                                                                                        |

## (政府自費) Molnupiravir 200mg (40顆/瓶) Lagevrio

| TAH Drug Code      | [OMOLS](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMOLS)                                                                                                                                                                                                                                                              |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | An Emergency Use Authorization (EUA) for the emergency use of Molnupiravir for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in certain adults who are at high-risk for progression to severe COVID-19.                                                                                                     |
| Dosing             | 800 mg (four 200-mg capsules) orally every 12 hours for 5 days with or without food; administer as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                       |
| Contraindications  | NOT for use in patients who are less than 18 years of age. NOT for initiation of treatment in patients requiring hospitalization due to COVID-19. NOT for use for longer than 5 consecutive days. NOT for use as pre-exposure or as post-exposure prophylaxis for prevention of COVID-19. Not recommended for use during pregnancy. |
| Adverse Effects    | Common Gastrointestinal: Diarrhea (2% to 3% )， Nausea (2% ) Neurologic: Dizziness (1% )， Headache (1% )                                                                                                                                                                                                                           |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                             |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information)                                                                                                                                                                                                                        |

